DYAIライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:23):

Stats
本日の出来高	24 842.00
平均出来高	23 009.00
時価総額	42.98M
EPS	$0 ( 2024-03-28 )
次の収益日	( $-0.0600 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.13
ATR14	$0.0270 (1.84%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Lucy Patrick K.	Buy	13 125	Stock Option
2024-04-11	Tarnok Michael P.	Sell	13 125	Stock Option
2024-04-11	Hazelton Joseph P	Buy	20 000	Stock Option
2024-03-13	Hazelton Joseph P	Buy	41 720	Common Stock
2024-03-13	Emalfarb Mark A	Buy	124 454	Common Stock

INSIDER POWER
81.65
Last 99 transactions
Buy: 3 507 936 \| Sell: 1 014 811

Dyadic International Inc 相関

10 最も正の相関
RMRM	0.973
TLGT	0.916
APOP	0.914
FCNCA	0.9
SVAC	0.897
TDAC	0.895
XERS	0.885
AQST	0.885
BRKS	0.885
BLRX	0.884

10 最も負の相関
MMAC	-0.936
NETE	-0.919
AMRB	-0.908
AEY	-0.897
BOCH	-0.893
TRUP	-0.89
PBHC	-0.887
EM	-0.884
MTP	-0.882
OBT	-0.878

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Dyadic International Inc 財務諸表

Annual	2023
収益:	$2.90M
総利益:	$922 957 (31.84 %)
EPS:	$-0.240

FY	2023
収益:	$2.90M
総利益:	$922 957 (31.84 %)
EPS:	$-0.240

FY	2022
収益:	$2.93M
総利益:	$807 110 (27.54 %)
EPS:	$-0.330

FY	2021
収益:	$2.40M
総利益:	$459 393 (19.11 %)
EPS:	$-0.470

Financial Reports:

No articles found.

Dyadic International Inc

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.